文献速递临床微生物质量管理与危急值

三种自动化药敏系统采用更新CLSI折点检测哌拉西林-他唑巴坦对肠杆菌目性能评估

Evaluation of Piperacillin-Tazobactam Testing against Enterobacterales by the Phoenix, MicroScan, and Vitek2 Tests Using Updated Clinical and Laboratory Standards Institute Breakpoints.
PubMed 文献 · J Clin Microbiol · 2023-01-31

本研究以参考肉汤微量稀释法为对照,评估Phoenix、MicroScan和Vitek2三种自动化系统对284株肠杆菌目检测哌拉西林-他唑巴坦MIC的性能。采用CLSI折点与FDA折点分别计算分类一致率及误差率,结果显示整体性能差异不大,但三种系统均存在高于期望的极重大误差率,MicroScan和Phoenix分类一致率偏低。

要点

  • Phoenix采用CLSI折点分类一致率84.4%,极重大误差4.2%,重大误差1.8%。
  • MicroScan采用CLSI折点极重大误差高达36.4%,分类一致率80.0%。
  • Vitek2采用CLSI折点分类一致率95.2%,极重大误差6.3%,重大误差0.0%。

核心结论

  • 三种自动化系统采用CLSI折点与FDA折点检测哌拉西林-他唑巴坦对肠杆菌目的整体性能无实质性差异。
  • 所有系统均存在高于期望的极重大误差率,MicroScan和Phoenix的分类一致率低于期望。
  • 实验室可考虑在自动化系统上采用修订的CLSI折点,但需注意检测性能挑战。

研究设计与样本

  • 以参考肉汤微量稀释法为对照,评估Phoenix(167株)、MicroScan(55株)和Vitek2(62株)检测哌拉西林-他唑巴坦对284株肠杆菌目的MIC性能。
  • 分别采用CLSI折点和FDA折点计算分类一致率、极重大误差和重大误差。

主要发现

  • Phoenix采用CLSI折点:分类一致率84.4%,极重大误差4.2%,重大误差1.8%;采用FDA折点:分类一致率85.0%,极重大误差4.3%,重大误差0.8%。
  • MicroScan采用CLSI折点:分类一致率80.0%,极重大误差36.4%,重大误差4.8%;采用FDA折点:分类一致率81.8%,极重大误差44.4%,重大误差0.0%。
  • Vitek2采用CLSI折点:分类一致率95.2%,极重大误差6.3%,重大误差0.0%;采用FDA折点:分类一致率96.8%,极重大误差0.0%,重大误差2.2%。

关键数值与推荐

  • 2022年CLSI基于大量数据更新肠杆菌目哌拉西林-他唑巴坦折点,历史折点不能预测治疗结局。
  • FDA尚未采纳修订折点,商业药敏系统制造商无法获得FDA对修订折点的许可。

临床怎么用

  • 实验室在自动化药敏系统上采用修订CLSI折点时应知晓可能存在性能挑战,尤其注意极重大误差。
  • 对于哌拉西林-他唑巴坦药敏结果,需结合临床和感染控制需求谨慎解读。

局限性

  • 各系统评估的菌株数量有限(Phoenix 167株、MicroScan 55株、Vitek2 62株)。
  • 所有系统均存在高于期望的极重大误差率,MicroScan和Phoenix分类一致率低于期望。
  • 研究未评估临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2022, the Clinical and Laboratory Standards Institute (CLSI) updated piperacillin-tazobactam (TZP) breakpoints for Enterobacterales, based on substantial data suggesting that historical breakpoints did not predict treatment outcomes for TZP. The U.S. Food and Drug Administration (FDA) has not yet adopted these breakpoints, meaning commercial manufacturers of antimicrobial susceptibility testing devices cannot obtain FDA clearance for the revised breakpoints. We evaluated the Phoenix (BD, Sparks, MD), MicroScan (Beckman Coulter, Sacramento, CA), and Vitek2 (bioMérieux, Durham, NC) TZP MICs compared to reference broth microdilution for a collection of 284 Enterobacterales isolates. Phoenix (n = 167 isolates) demonstrated 84.4% categorical agreement (CA), with 4.2% very major errors (VMEs) and 1.8% major errors (MEs) by CLSI breakpoints. In contrast, CA was 85.0% with 4.3% VMEs and 0.8% MEs for the Phoenix with FDA breakpoints. MicroScan (n = 55 isolates) demonstrated 80.0% CA, 36.4% VMEs, and 4.8% MEs by CLSI breakpoints and 81.8% CA, 44.4% VMEs, and 0.0% MEs by FDA breakpoints. Vitek2 (n = 62 isolates) demonstrated 95.2% CA, 6.3% VMEs, and 0.0% MEs by CLSI and 96.8% CA, 0.0% VMEs, and 2.2% MEs by FDA breakpoints. Overall, the performance of the test systems was not substantially different using CLSI breakpoints off-label than using on-label FDA breakpoints. However, limitations were noted with higher-than-desired VME rates (all three systems) and lower-than-desired CA (MicroScan and Phoenix). Laboratories should consider adoption of the revised CLSI breakpoints with automated test systems but be aware that some performance challenges exist for testing TZP on automated systems, regardless of breakpoints applied.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Manuel C, Maynard R, Abbott A, et al. Evaluation of Piperacillin-Tazobactam Testing against Enterobacterales by the Phoenix, MicroScan, and Vitek2 Tests Using Updated Clinical and Laboratory Standards Institute Breakpoints. J Clin Microbiol. 2023. PMID: 36719243. doi:10.1128/jcm.01617-22

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。